The warrant exercise is a routine capital event with no material impact on the stock. Monitor upcoming quarterly earnings and pipeline catalysts for directional signals.
ASND drugs
ASND drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 30 $266.72entry
- T+1 · 5mo ago +0.40%α +0.54% · $267.79
- T+5 · 4mo ago +0.45%α −0.15% · $267.92
- T+20 · 4mo ago −4.99%α −3.96% · $253.42
- T+60 · 8w ago −16.34%α −19.91% · $223.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ascendis Pharma reported the closing of a warrant exercise window on June 29, 2026, resulting in the issuance of 177,267 ordinary shares at an average cash consideration of approximately $121.57 per share. The company's share capital increased to DKK 66,189,926, and the articles of association were amended accordingly. This is a routine administrative filing with no material impact on the company's operations or financial outlook.
Key Facts
- 177,267 ordinary shares issued upon exercise of warrants at an average cash consideration of approximately $121.57 per share.
- Share capital increased to DKK 66,189,926.
- Articles of association amended to reflect the capital increase.
- Exercise window closed on June 29, 2026.
Financial Impact
Approximately $21.5 million in cash proceeds from warrant exercises, negligible dilution relative to $16.6B market cap.
Risk Factors
- Minimal dilution from share issuance, but immaterial at current scale.
- No new business or pipeline updates in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-288414 |
| Document: d22299d6k.htm | 0001193125-26-288414 |
| Document: 0001193125-26-288414-index-headers.html | 0001193125-26-288414 |
| Document: 0001193125-26-288414-index.html | 0001193125-26-288414 |
| Document: 0001193125-26-288414.txt | 0001193125-26-288414 |
Track record
41 reports on ASND
14 of 19 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 25 of 27 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers